Key result
SARS-CoV-2 infection linked to progressive coronary atherosclerosis potentially driven by systemic hyperinflammation.
Why the study?
There is conflicting evidence from clinical and scientific studies regarding COVID-19-related cardiovascular disease and its impact on atherosclerosis progression.
Case Report (n=1)
SARS-CoV-2 infection may accelerate the progression of coronary atherosclerosis and precipitate myocardial infarction through systemic hyperinflammation.
Case suggests possible post-COVID atherosclerosis acceleration; hypothesis-generating and should not change practice without prospective data.
The past 2020 was marked by the SARS-CoV-2 pandemic, which entailed an increased risk of mortality in patients with previous cardiovascular diseases (CVD) or with various risk factors (RF) of atherosclerosis. There is conflicting evidence from clinical and scientific studies of COVID-19-related cardiovascular disease. One of the features of the new SARS-CoV-2 infection is its ability to induce a systemic hyperinflammatory response, accompanied by instability of atherosclerotic plaques. In this sense, the course of atherosclerosis becomes accelerated, or rapidly progressing. The article presents a clinical case demonstrating the progressive course of coronary atherosclerosis in a patient with several interrelated factors, including the novel SARS-CoV-2 coronavirus infection.
No takes yet. Share an insight, caveat, or question.
Ложкина et al. (2021) conducted a case report in Coronary atherosclerosis and SARS-CoV-2 infection (n=1). SARS-CoV-2 infection was evaluated on Progressive course of coronary atherosclerosis. SARS-CoV-2 infection was associated with a progressive course of coronary atherosclerosis in a clinical case, potentially driven by a systemic hyperinflammatory response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: